Grupos Investigadores

Líneas de Investigación

  • PET de actividad dopaminérgica (11C-DTBZ) en el diagnóstico precoz y seguimiento de pacientes con enfermedad de Parkinson.
  • PET con aminoácidos (11C-Metionina) en gliomas del SNC.
  • PET Tau (18F-THK5351) y PET Amiloide en pacientes con deterioro cognitivo.
  • PET Tau (18F-THK5351) en pacientes con Parálisis Supranuclear Progresiva.
  • PET FDG en neurodegeneración: síndrome parkinsonianos de origen incierto.
  • PET FDG en la selección pacientes sordos bilaterales asimétricos candidatos a Implantes cocleares.
  • PET Amiloide y PET FDG en el diagnóstico de la enfermedad de Alzheimer en pacientes con deterioro cognitivo.

Palabras Clave

  • Tau Imaging
  • Parkinson
  • PET
  • Neuroimaging
  • Neurodegeneration
  • Glioma
  • Dopaminergic Imaging
  • Cognitive impairment
  • Amyloid Imaging
  • Amino acid imaging

Publicaciones Científicas desde 2018

  • Autores: Rodríguez Fraile, María Macarena (Autor de correspondencia); Tamayo-Alonso, P.; Rosales Castillo, Juan Jose; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.41 N° 2 2022 págs. 126 - 135
    Resumen
    El cáncer de próstata (CP) es el tumor más frecuente en varones en Occidente y la quinta causa de muerte relacionada con el cáncer. El uso de radioligandos antígeno prostático específico de membrana (PSMA) ha supuesto un importante avance tanto en su diagnóstico, a través de la imagen molecular de tomografía por emisión de positrones (PET), como en su tratamiento en fases avanzadas de la enfermedad. En este artículo, se hace una revisión de la aportación de los estudios PET con radioligandos PSMA en la estadificación inicial, en la detección tumoral en la recidiva bioquímica (elevación del antígeno prostático específico [PSA]) tras un tratamiento con intención curativa, y en los estadios más avanzados de la enfermedad (CP resistente a la castración o CPRC). Se analiza, además, la aportación de la terapia con radioligandos PSMA (PSMA-TRL) en pacientes con CPRC que progresan a la terapia estándar.
  • Autores: Casanovas, M. M.; Pubul, V.; Bello, P.; et al.
    Revista: JOURNAL OF NEUROENDOCRINOLOGY
    ISSN 0953-8194 Vol.34 N° SupL. 1 2022 págs. 155
  • Autores: Valentí Azcárate, Rafael (Autor de correspondencia); Irimia Sieira, Pablo; Esparragosa Vázquez, Inés; et al.
    Revista: NEUROLOGIA
    ISSN 0213-4853 Vol.36 N° 1 2021 págs. 88 - 89
  • Autores: Chetelat, G. (Autor de correspondencia); Arbizu Lostao, Javier; Barthel, H.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° 8 2021 págs. 2320 - 2324
  • Autores: Rosales Castillo, Juan Jose (Autor de correspondencia); Toledano Illán, Carlos; Riverol Fernández, Mario; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° 3 2021 págs. 947 - 948
  • Autores: Grisanti Vollbracht, Fabiana Lucrecia (Autor de correspondencia); Prieto Azcárate, Elena; Bastidas Tamayo, Juan Fernando; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° 10 2021 págs. 3048 - 3057
    Resumen
    Introduction: Volume changes induced by selective internal radiation therapy (SIRT) may increase the possibility of tumor resection in patients with insufficient future liver remnant (FLR). The aim was to identify dosimetric and clinical parameters associated with contralateral hepatic hypertrophy after lobar/extended lobar SIRT with 90Y-resin microspheres. Materials and methods: Patients underwent 90Y PET/CT after lobar or extended lobar (right + segment IV) SIRT. 90Y voxel dosimetry was retrospectively performed (PLANET Dose; DOSIsoft SA). Mean absorbed doses to tumoral/non-tumoral-treated volumes (NTL) and dose-volume histograms were extracted. Clinical variables were collected. Patients were stratified by FLR at baseline (T0-FLR): < 30% (would require hypertrophy) and ¿ 30%. Changes in volume of the treated, non-treated liver, and FLR were calculated at < 2 (T1), 2-5 (T2), and 6-12 months (T3) post-SIRT. Univariable and multivariable regression analyses were performed to identify predictors of atrophy, hypertrophy, and increase in FLR. The best cut-off value to predict an increase of FLR to ¿ 40% was defined using ROC analysis. Results: Fifty-six patients were studied; most had primary liver tumors (71.4%), 40.4% had cirrhosis, and 39.3% had been previously treated with chemotherapy. FLR in patients with T0-FLR < 30% increased progressively (T0: 25.2%; T1: 32.7%; T2: 38.1%; T3: 44.7%). No dosimetric parameter predicted atrophy. Both NTL-Dmean and NTL-V30 (fraction of NTL exposed to ¿ 30 Gy) were predictive of increase in FLR in patients with T0 FLR < 30%, the latter also in the total cohort of patients. Hypertrophy was not significantly associated with tumor dose or tumor size. When ¿ 49% of NTL received ¿ 30 Gy, FLR increased to ¿ 40% (accuracy: 76.4% in all patients and 80.95% in T0-FLR < 30% patients). Conclusion: NTL-Dmean and NTL exposed to ¿ 30 Gy (NTL-V30) were most significantly associated with increase in FLR (particularly among patients with T0-FLR < 30%). When half of NTL received ¿ 30 Gy, FLR increased to ¿ 40%, with higher accuracy among patients with T0-FLR < 30%.
  • Autores: Domínguez Echávarri, Pablo Daniel; Manrique Huarte, Raquel; Suárez Vega, Victor Manuel; et al.
    Revista: FRONTIERS IN SURGERY
    ISSN 2296-875X Vol.8 2021 págs. 673847
    Resumen
    Background: Endolymphatic hydrops (EH) is the histopathological hallmark of Ménière's disease (MD) and has been found by in vivo magnetic resonance imaging (MRI) in patients with several inner ear syndromes without definite MD criteria. The incidence and relevance of this finding is under debate. Purpose: The purpose of the study is to evaluate the prevalence and characteristics of EH and audiovestibular test results in groups of patients with fluctuating audiovestibular symptoms not fulfilling the actual criteria for definite MD and compare them with a similar group of patients with definite MD and a group of patients with recent idiopathic sudden neurosensory hearing loss (ISSNHL). Material and Methods: 170 patients were included, 83 with definite MD, 38 with fluctuating sensorineural hearing loss, 34 with recurrent vertigo, and 15 with ISSNHL. The clinical variables, audiovestibular tests, and EH were evaluated and compared. Logistic proportional hazard models were used to obtain the odds ratio for hydrops development, including a multivariable adjusted model for potential confounders. Results: No statistical differences between groups were found regarding disease duration, episodes, Tumarkin spells, migraine, vascular risk factors, or vestibular tests; only hearing loss showed differences. Regarding EH, we found significant differences between groups, with odds ratio (OR) for EH presence in definite MD group vs. all other patients of 11.43 (4.5-29.02; p < 0.001). If the ISSNHL group was used as reference, OR was 55.2 (11.9-253.9; p < 0.001) for the definite MD group, 9.9 (2.1-38.9; p = 0.003) for the recurrent vertigo group, and 5.1 (1.2-21.7; p = 0.03) for the group with fluctuating sensorineural hearing loss. Conclusion: The percentage of patients with EH varies between groups. It is minimal in the ISSNHL group and increases in groups with increasing fluctuating audiovestibular symptoms, with a rate of severe EH similar to the known rate of progression to definite MD in those groups, suggesting that presence of EH by MRI could be related to the risk of progression to definite MD. Thus, EH imaging in these patients is recommended.
  • Autores: Martínez Valbuena, Iván; Valentí Azcárate, Rafael; Amat-Villegas, I.; et al.
    Revista: ACTA NEUROPATHOLOGICA COMMUNICATIONS
    ISSN 2051-5960 Vol.9 N° 1 2021 págs. 64
    Resumen
    Protein misfolding diseases refer to a variety of disorders that develop as a consequence of the misfolding of proteins in various organs. The etiologies of Parkinson's and Alzheimer's disease remain unclear, but it seems that type two diabetes and other prediabetic states could contribute to the appearance of the sporadic forms of these diseases. In addition to amylin deposition, other amyloidogenic proteins implicated in the pathophysiology of neurodegenerative diseases could have important roles in the pathogenesis of this disease. As we have previously demonstrated the presence of alpha-synuclein deposits in the pancreas of patients with synucleinopathies, as well as tau and A beta deposits in the pancreatic tissue of Alzheimer's disease patients, we studied the immunoreactivity of amylin, tau and alpha-synuclein in the pancreas of 138 subjects with neurodegenerative diseases or type two diabetes and assessed whether the pancreatic beta-cells of these subjects present cooccurrence of misfolded proteins. Furthermore, we also assessed the pancreatic expression of prion protein (PrP) in these subjects and its interaction, both in the pancreas and brain, with alpha-synuclein, tau, A beta and amylin. Our study shows, for the first time, that along with amylin, pancreatic alpha-synuclein, A beta, PrP and tau may contribute together to the complex pathophysiology of type two diabetes and in the appearance of insulin resistance in Alzheimer's and Parkinson's disease. Furthermore, we show that the same mixed pathologies that are observed in the brains of patients with neurodegenerative diseases are also present outside the nervous system. Finally, we provide the first histological evidence of an interaction between PrP and A beta, alpha-synuclein, amylin or tau in the pancreas and locus coeruleus. These findings will shed more light on the common pathological pathways shared by neurodegenerative diseases and type two diabetes, benefiting the exploration of common therapeutic strategies to prevent or treat these devastating amyloid diseases.
  • Autores: Rodríguez Fraile, María Macarena (Autor de correspondencia); Ezponda Casajús, Ana; Grisanti Vollbracht, Fabiana Lucrecia; et al.
    Revista: EJNMMI RESEARCH
    ISSN 2191-219X Vol.11 N° 1 2021 págs. 23
    Resumen
    Purpose: To determine which imaging method used during radioembolization (RE) work-up: contrast-enhanced computed tomography (CECT), 99mTc-MAA-SPECT/CT or cone beam-CT (CBCT), more accurately predicts the final target volume (TgV) as well as the influence that each modality has in the dosimetric calculation. Methods: TgVs from 99mTc-MAA-SPECT/CT, CECT and CBCT were consecutively obtained in 24 patients treated with RE and compared with 90Y PET/CT TgV. Using the TgVs estimated by each imaging modality and a fictitious activity of 1 GBq, the corresponding absorbed doses by tumor and non-tumoral parenchyma were calculated for each patient. The absorbed doses for each modality were compared with the ones obtained using 90Y PET/CT TgV. Results: 99mTc-MAA-SPECT/CT predicted 90Y PET/CT TgV better than CBCT or CECT, even for selective or superselective administrations. Likewise, 99mTc-MAA-SPECT/CT showed dosimetric values more similar to those obtained with 90Y PET/CT. Nevertheless, CBCT provided essential information for RE planning, such as ensuring the total coverage of the tumor and, in cases with more than one feeding artery, splitting the activity according to the volume of tumor perfused by each artery. Conclusion: The joint use of 99mTc-MAA-SPECT/CT and CBCT optimizes dosimetric planning for RE procedures, enabling a more accurate personalized approach.
  • Autores: Carmona Abellán, María del Mar (Autor de correspondencia); Trzeciak, Malwina; Recio Fernández, Miriam; et al.
    Revista: BRAIN SCIENCES
    ISSN 2076-3425 Vol.11 N° 3 2021 págs. 385
    Resumen
    Background: Both cerebral vascular disorders and cognitive decline increase in incidence with age. The role of cerebral vascular disease and hemodynamic changes in the development of cognitive deficits is controversial. The objective of this study was to assess the cardiovascular response during cardiac stress testing in neurologically asymptomatic individuals who developed cognitive impairment several years after previous cardiac stress testing. (2) Methods: This was a retrospective cohort study of patients who underwent cardiac stress testing between January 2001 and December 2010. Patients were followed up until May 2015, and we selected those who developed cognitive dysfunction including dementia, mild cognitive impairment, and subjective cognitive decline, after the stress test. Heart rate and blood pressure both at rest and at peak exercise, and the mean R-R interval at rest were recorded. For each patient who developed cognitive impairment, we selected one matched control who did not show cognitive decline by the end of the follow-up period. (3) Results: From the cohort of 7224 patients, 371 developed cognitive impairment; of these, 186 (124 men) met the inclusion criteria, and 186 of the other patients were selected as matched controls. During follow-up, cognitive impairment appeared 6.2 +/- 4.7 years after the cardiac stress test. These patients who had subsequently developed cognitive impairment had significantly lower at-rest systolic, diastolic, and mean blood...
  • Autores: Mitjavila-Casanovas, M.; Bello, P.; Pubul, V.; et al.
    Revista: JOURNAL OF NEUROENDOCRINOLOGY
    ISSN 0953-8194 Vol.33 N° Supl. 1 2021 págs. 191
  • Autores: Prieto Azcárate, Elena; Puente, V.; Bastidas Tamayo, Juan Fernando; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° Supl. 1 2021 págs. S279 - S280
  • Autores: Casanovas, M. M.; Bello, P.; Pubul, V.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° Supl. 1 2021 págs. S333 - S334
  • Autores: Bronte Viedma, Angela; Echaide Itarte, Ana María; Rosales Castillo, Juan Jose; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.48 N° Supl. 1 2021 págs. S168
  • Autores: Rodríguez Fraile, María Macarena (Autor de correspondencia); Cózar-Santiago, M. P.; Sabaté-Llobera, A.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.39 N° 1 2020 págs. 57 - 66
    Resumen
    Colorectal cancer is the third most frequent cancer worldwide. Although its incidence is increasing, mainly in those aged under50, mortality has decreased by 50% in the more developed countries, principally due to the adoption of new practices in prevention, diagnosis and treatment. In particular, the various diagnostic imaging modalities allow improved therapeutic decision-making, evaluation of the response and early detection of recurrence. The aim of this paper is to review the available scientific evidence on the value of positron emission tomography with 18F-FDG (18F-FDG PET/CT) in the colorectal cancer, with special emphasis on the indications of the guidelines and recommendations of the main international scientific associations regarding this imaging technique.
  • Autores: Guillen Valderrama, Edgar Fernando; Rosales Castillo, Juan Jose; Lisei, D.; et al.
    Revista: CLINICAL AND TRANSLATIONAL IMAGING
    ISSN 2281-5872 Vol.8 2020 págs. 127 - 140
    Resumen
    Purpose We aim to present and critically evaluate the use of FDG-PET in the differential diagnosis between dementing conditions including Alzheimer disease (AD), frontotemporal dementia (FTD) and its variants, vascular dementia (VaD) and pseudodepressive dementia. Methods This review is based on the available consensus recommendations for the use of FDG-PET and current clinical diagnostic criteria. In addition, we updated these reviews with relevant publications in the field after conducting a literature search during the last 5 years through predefined keyword strings relating to the specific terms related to the diseases covered in this review and a common part ('FDG-PET'). Results Neurodegenerative disease are complex groups of several forms of dementia and their clinical diagnostic criteria are progressively incorporating imaging biomarkers as a supporting tool. The role of FDG-PET is currently increasing as part of the clinical practice supporting the clinical diagnosis of AD (at both mild cognitive impairment-MCI-and early dementia stages), FTD and its variants, as well as VaD and pseudodepressive dementia. The pattern of AD is well defined and its negative predicted value may help the differential diagnosis when comorbidities like vascular disease or depression are present. However, the formal evidence supporting the use of FDG-PET is reasonable for MCI due to AD, and the differential diagnosis between FTD and AD, but lacking for the remaining clinical uses. Interestingly, the evidence provided during the last years reinforces these recommendations and gives additional clues about the usefulness of semiquantitative methods in addition to visual reading. Conclusion The large experience accumulated using FDG-PET for the differential diagnosis of the main conditions with dementia has been translated into more formal evidence to support its clinical use. Although FDG-PET form currently part of the clinical practice in many countries, there is still a lack of studies using standardized analysis that confirm specific patterns at individual level.
  • Autores: Esparragosa Vázquez, Inés (Autor de correspondencia); Valentí Azcárate, Rafael; Gállego Pérez de Larraya, Jaime; et al.
    Revista: NEUROLOGIA
    ISSN 0213-4853 Vol.35 N° 9 2020 págs. 690 - 692
  • Autores: Morales Lozano, María Isabel (Autor de correspondencia); Erhard García, Álvaro; Lozano Escario, María Dolores; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.39 N° 2 2020 págs. 102 - 103
  • Autores: Barthel, H. (Autor de correspondencia); Arbizu Lostao, Javier; Drzezga, A. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° 8 2020 págs. 1787 - 1790
  • Autores: Moreno Ajona, David; Prieto Azcárate, Elena; Grisanti Vollbracht, Fabiana Lucrecia; et al.
    Revista: DIAGNOSTICS
    ISSN 2075-4418 Vol.10 N° 6 2020 págs. 356
    Resumen
    Brain positron emission tomography imaging with 18Fluorine-fluorodeoxyglucose (FDG-PET) has demonstrated utility in suspected autoimmune encephalitis. Visual and/or assisted image reading is not well established to evaluate hypometabolism/hypermetabolism. We retrospectively evaluated patients with autoimmune encephalitis between 2003 and 2018. Patients underwent EEG, brain magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) sampling and autoantibodies testing. Individual FDG-PET images were evaluated by standard visual reading and assisted by voxel-based analyses, compared to a normal database. For the latter, three different methods were performed: two based on statistical surface projections (Siemens syngo.via Database Comparison, and 3D-SSP Neurostat) and one based on statistical parametric mapping (SPM12). Hypometabolic and hypermetabolic findings were grouped to identify specific patterns. We found six cases with definite diagnosis of autoimmune encephalitis. Two cases had anti-LGI1, one had anti-NMDA-R and two anti-CASPR2 antibodies, and one was seronegative.F-18-FDG-PET metabolic abnormalities were present in all cases, regardless of the method of analysis. Medial-temporal and extra-limbic hypermetabolism were more clearly depicted by voxel-based analyses. We found autoantibody-specific patterns in line with the literature. Statistical surface projection (SSP) methods (Neurostat and syngo.via Database Comparison) were more sensitive and localized larger hypermetabolic areas. As it may lead to comparable and accurate results, visual analysis of FDG-PET studies for the diagnosis of autoimmune encephalitis benefits from voxel-based analysis, beyond the approach based on MRI, CSF sample and EEG.
  • Autores: Morales Lozano, María Isabel; Erhard García, Álvaro; Lozano Escario, María Dolores; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.39 N° 2 2020 págs. 102 - 103
  • Autores: Martí Andrés, Gloria María (Autor de correspondencia); Van Bomel, L.; Meles, SK.; et al.
    Revista: MOVEMENT DISORDERS
    ISSN 0885-3185 Vol.35 N° 11 2020 págs. 2009 - 2018
    Resumen
    It remains unclear whether the supportive imaging features described in the diagnostic criteria for progressive supranuclear palsy (PSP) are suitable for the full clinical spectrum. The aim of the current study was to define and cross-validate the pattern of glucose metabolism in the brain associated with a diagnosis of different PSP variants. A retrospective multicenter cohort study performed on 73 PSP patients who were referred for a fluorodeoxyglucose positron emission tomography PET scan: PSP-Richardson's syndrome, n = 47; PSP-parkinsonian variant, n = 18; and progressive gait freezing, n = 8. In addition, we included 55 healthy controls and 58 Parkinson's disease (PD) patients. Scans were normalized by global mean activity. We analyzed the regional differences in metabolism between the groups. Moreover, we applied a multivariate analysis to obtain a PSP-related pattern that was cross-validated in independent populations at the individual level. Group analysis showed relative hypometabolism in the midbrain, basal ganglia, thalamus, and frontoinsular cortices and hypermetabolism in the cerebellum and sensorimotor cortices in PSP patients compared with healthy controls and PD patients, the latter with more severe involvement in the basal ganglia and occipital cortices. The PSP-related pattern obtained confirmed the regions described above. At the individual level, the PSP-related pattern showed optimal diagnostic accuracy to distinguish between PSP and healthy controls (sensitivity, 80.4%; specificity, 96.9%) and between PSP and PD (sensitivity, 80.4%; specificity, 90.7%). Moreover, PSP-Richardson's syndrome and PSP-parkinsonian variant patients showed significantly more PSP-related pattern expression than PD patients and healthy controls. The glucose metabolism assessed by fluorodeoxyglucose PET is a useful and reproducible supportive diagnostic tool for PSP-Richardson's syndrome and PSP-parkinsonian variant.
  • Autores: Sánchez-Orduz, L.; Pérez-Larraya, J. G. ; Grisanti Vollbracht, Fabiana Lucrecia; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.39 N° 2 2020 págs. 92 - 95
    Resumen
    Early immunotherapy is of paramount importance for a positive outcome in patients suffering acute encephalitis of autoimmune origin (AIE). A new approach for early diagnosis based on dinical presentation and complementary tests has been proposed, but not all these tests show positive findings in the first weeks. While common forms of AIE (anti-LGI-1 and anti-NMDAR antibodies) exhibit consistent 18Fluor-fluorodeoxiglucose (FDG-PET) patterns in many cases, the anti-Caspr2 form of AIE is infrequent and FDG-PET patterns have not been well characterized. In our experience, FDG-PET in anti-Caspr2 limbic encephalitis shows medial temporal hypermetabolism and diffuse cortical hypometabolism, even in the absence of findings in these tests. However, it is necessary to standardize PET image analysis by means of visual and voxel-based methods compared to normal databases to define the areas of pathological metabolism that may go unnoticed when using visual analysis exclusively.
  • Autores: Martí Andrés, Gloria María; Van Bommel, L.; Meles, S.; et al.
    Revista: MOVEMENT DISORDERS
    ISSN 0885-3185 Vol.35 2020 págs. S116 - S116
  • Autores: Casanovas, M. M. ; Bayonas, A. C. ; Bello, P. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° SUPPL 1 2020 págs. S86 - S87
  • Autores: Carmona-Bayonas, A.; Mitjavila, C. M.; Bello, P. ; et al.
    Revista: NEUROENDOCRINOLOGY
    ISSN 0028-3835 Vol.110 2020 págs. 251 - 251
  • Autores: van de Giessen, E.; Arbizu Lostao, Javier; Cecchin, D.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° SUPPL 1 2020 págs. S22 - S22
  • Autores: Grisanti Vollbracht, Fabiana Lucrecia; Rodrigo, P. ; Bastidas Tamayo, Juan Fernando; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° Suppl. 1 2020 págs. S58 - S58
  • Autores: Prieto Azcárate, Elena; Marti Climent, Josep María; Aquerreta Beola, Jesús Dámaso; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° SUPPL 1 2020 págs. S81 - S81
  • Autores: Martí Andrés, Gloria María; Rosales Castillo, Juan Jose; Prieto Azcárate, Elena; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.47 N° SUPPL 1 2020 págs. S94 - S94
  • Autores: Perez-Grijalba, V.; Romero, J. ; Pesini, P. (Autor de correspondencia); et al.
    Revista: JPAD
    ISSN 2274-5807 Vol.6 N° 1 2019 págs. 34 - 41
    Resumen
    BACKGROUND: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. OBJECTIVES: This study evaluated the potential of plasma beta-amyloid (A beta) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. DESIGN: Total plasma A beta 42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. RESULTS: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). CONCLUSIONS: TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
  • Autores: Law, I. (Autor de correspondencia); Albert, N. L.; Arbizu Lostao, Javier; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.46 N° 3 2019 págs. 540 - 557
    Resumen
    These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.
  • Autores: Pérez Grijalba, Virginia; Arbizu Lostao, Javier; Judith Romero; et al.
    Revista: ALZHEIMER'S RESEARCH & THERAPY
    ISSN 1758-9193 Vol.11 N° 1 2019 págs. 96
    Resumen
    BACKGROUND: To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aß) levels with the presence of pathological accumulation of Aß in the brain measured by amyloid-PET. Both plasma Aß42/40 ratio alone or combined with an FDG-PET-based biomarker of neurodegeneration were assessed as potential AD biomarkers. METHODS: We included 39 cognitively normal subjects and 20 patients with mild cognitive impairment from the AB255 Study who had undergone PiB-PET scans. Total Aß40 and Aß42 levels in plasma (TP42/40) were quantified using ABtest kits. Subjects were dichotomized as Aß-PET positive or negative, and the ability of TP42/40 to detect Aß-PET positivity was assessed by logistic regression and receiver operating characteristic analyses. Combination of plasma Aß biomarkers and FDG-PET was further assessed as an improvement for brain amyloidosis detection and diagnosis classification. RESULTS: Eighteen (30.5%) subjects were Aß-PET positive. TP42/40 ratio alone identified Aß-PET status with an area under the curve (AUC) of 0.881 (95% confidence interval [CI]¿=¿0.779-0.982). Discriminating performance of TP42/40 to detect Aß-PET-positive subjects yielded sensitivity and specificity values at Youden's cutoff of 77.8% and 87.5%, respectively, with a positive predictive value of 0.732 and negative predictive value of 0.900. All these parameters improved after adjusting the model for significant covariates. Applying TP42/40 as the first screening tool in a sequential diagnostic work-up would reduce the number of Aß-PET scans by 64%. Combination of both FDG-PET scores and plasma Aß biomarkers was found to be the most accurate Aß-PET predictor, with an AUC of 0.965 (95% CI¿=¿0.913-0.100). CONCLUSIONS: Plasma TP42/40 ratio showed a relevant and significant potential as a screening tool to identify brain Aß positivity in preclinical and prodromal stages of Alzheimer's disease.
  • Autores: Casanovas, M. M. ; Field, C.; Bello, P.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.46 N° Supl. 1 2019 págs. S93 - S93
  • Autores: Mitjavila, M. ; Percovich, J. C. ; Pasin, M. C. P. ; et al.
    Revista: NEUROENDOCRINOLOGY
    ISSN 0028-3835 Vol.108 N° Supl. 1 2019 págs. 223 - 223
  • Autores: Arbizu Lostao, Javier; Martí Andrés, Gloria María; Lorenzo-Bosquet, C.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S317 - S318
  • Autores: Martí Andrés, Gloria María; Riverol Fernández, Mario; Valentí Azcárate, Rafael; et al.
    Revista: MOVEMENT DISORDERS
    ISSN 0885-3185 Vol.34 2019 págs. S810 - S811
  • Autores: Arbizu Lostao, Javier (Autor de correspondencia); Festari, C.; Altomare, D.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1497 - 1508
    Resumen
    We aim to report the quality of accuracy studies investigating the utility of [F-18]fluorodeoxyglucose (FDG)-PET in supporting the diagnosis of prodromal Alzheimer's Disease (AD), frontotemporal lobar degeneration (FTLD) and prodromal dementia with Lewy bodies (DLB) in mild cognitive impairment (MCI) subjects, and the corresponding recommendations made by a panel of experts. Seven panellist, four from the European Association of Nuclear Medicine, and three from the European Academy of Neurology, produced recommendations taking into consideration the incremental value of FDG-PET, as added on clinical-neuropsychological examination, to ascertain the aetiology of MCI (AD, FTLD or DLB). A literature search using harmonized population, intervention, comparison, and outcome (PICO) strings was performed, and an evidence assessment consistent with the European Federation of Neurological Societies guidance was provided. The consensual recommendation was achieved based on Delphi rounds. Fifty-four papers reported the comparison of interest. The selected papers allowed the identification of FDG patterns that characterized MCI due to AD, FTLD and DLB. While clinical outcome studies supporting the diagnosis of MCI due to AD showed varying accuracies (ranging from 58 to 100%) and varying areas under the receiver-operator characteristic curves (0.66 to 0.97), no respective data were identified for MCI due to FTLD or for MCI due to DLB. However, the high negative predictive value of FDG-PET and the existence of different disease-specific patterns of hypometabolism support the consensus recommendations for the clinical use of this imaging technique in MCI subjects. FDG-PET has clinical utility on a fair level of evidence in detecting MCI due to AD. Although promising also in detecting MCI due to FTLD and MCI due to DLB, more research is needed to ultimately judge the clinical utility of FDG-PET in these entities.
  • Autores: Drzezga, A. (Autor de correspondencia); Altomare, D.; Festari, C. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1487 - 1496
    Resumen
    To assess the clinical utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of increased risk for Alzheimer's disease (AD) as defined by: subjective cognitive decline (SCD), evidence of cerebral amyloid-pathology, apolipoprotein E (APOE) epsilon 4-positive genotype, or autosomal dominant forms of AD (ADAD) in asymptomatic stages. A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on three different diagnostic scenarios. The level of empirical study evidence for the use of FDG-PET to detect meaningful early signs of neurodegeneration was considered to be poor for ADAD and lacking for SCD and asymptomatic persons at risk, based on APOE epsilon 4-positive genotype or cerebral amyloid pathology. Consequently, and consistent with current diagnostic criteria, panelists decided not to recommend routine clinical use of FDG-PET in these situations and to currently mainly reserve it for research purposes. Currently, there is limited evidence on which to base recommendations regarding the clinical routine use of FDG-PET to detect diagnostically meaningful early signs of neurodegeneration in asymptomatic subjects with ADAD, with APOE epsilon 4-positive genotype, or with cerebral amyloid pathology, and in subjects with SCD. Future prospective studies are warranted and in part already ongoing, aiming to assess the added value of FDG-PET in this context beyond research applications.
  • Autores: Verger, A. (Autor de correspondencia); Arbizu Lostao, Javier; Law, I.
    Revista: THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1824-4785 Vol.62 N° 3 2018 págs. 254 - 266
    Resumen
    Positron emission tomography (PET) using radiolabeled amino-acids was recently recommended by the Response Assessment in Neuro-Oncology (RANO) working group as an additional tool in the diagnostic assessment of brain tumors. The aim of this review is to summarize available literature data on the role of amino-acid PET imaging in high-grade gliomas (HGGs), with regard to diagnosis, treatment planning and follow-up of these tumors. Indeed, amino-acid PET applications are multiple throughout the evolution of HGGs. However, certain limitations such as lack of specificity, uncertain value for grading and prognostication or the limited data for treatment monitoring should to be taken into account, the latter of which are further developed in this review. Notwithstanding these limitations, amino-acid PET is becoming increasingly accessible in many nuclear medicine centers. Larger prospective cohort prospective studies are thus needed in order to increase the clinical value of this modality and enable its extended use to the largest number of patients.
  • Autores: Nobili, F. (Autor de correspondencia); Festari, C. ; Altomare, D.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1557 - 1566
    Resumen
    To review literature until November 2015 and reach a consensus on whether automatic semi-quantification of brain FDG-PET is useful in the clinical setting for neurodegenerative disorders. A literature search was conducted in Medline, Embase, and Google Scholar. Papers were selected with a lower limit of 30 patients (no limits with autopsy confirmation). Consensus recommendations were developed through a Delphi procedure, based on the expertise of panelists, who were also informed about the availability and quality of evidence, assessed by an independent methodology team. Critical outcomes were available in nine among the 17 papers initially selected. Only three papers performed a direct comparison between visual and automated assessment and quantified the incremental value provided by the latter. Sensitivity between visual and automatic analysis is similar but automatic assessment generally improves specificity and marginally accuracy. Also, automated assessment increases diagnostic confidence. As expected, performance of visual analysis is reported to depend on the expertise of readers. Tools for semi-quantitative evaluation are recommended to assist the nuclear medicine physician in reporting brain FDG-PET pattern in neurodegenerative conditions. However, heterogeneity, complexity, and drawbacks of these tools should be known by users to avoid misinterpretation. Head-to-head comparisons and an effort to harmonize procedures are encouraged.
  • Autores: Walker, Z. (Autor de correspondencia); Gandolfo, F. ; Orini, S.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1534 - 1545
    Resumen
    There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome. We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET based on published evidence and expert opinion. Of 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET for all three clinical scenarios based on nonquantitative evidence of clinical utility. Despite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.
  • Autores: Domínguez Echávarri, Pablo Daniel; Naganawa, S.
    Revista: EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
    ISSN 0937-4477 Vol.275 N° 1 2018 págs. 311 - 312
  • Autores: Agosta, F. (Autor de correspondencia); Altomare, D.; Festari, C.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1546 - 1556
    Resumen
    To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients. Four comprehensive literature searches were conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on these four diagnostic scenarios. The availability of evidence was good for FDG-PET utility to support the diagnosis of ALS, poor for identifying presymptomatic subjects carrying HD mutation who will convert to HD, and lacking for identifying cognitive-related metabolic changes in both ALS and HD. After the Delphi consensual procedure, the panel did not support the clinical use of FDG-PET for any of the four scenarios. Relative to other neurodegenerative diseases, the clinical use of FDG-PET in ALS and HD is still in its infancy. Once validated by disease-control studies, FDG-PET might represent a potentially useful biomarker for ALS diagnosis. FDG-PET is presently not justified as a routine investigation to predict conversion to HD, nor to detect evidence of brain dysfunction justifying cognitive decline in ALS and HD.
  • Autores: Merino-Casabiel, X.; Aller, J.; Arbizu Lostao, Javier; et al.
    Revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
    ISSN 1699-048X Vol.20 N° 12 2018 págs. 1522 - 1528
    Resumen
    PurposeGastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors.MethodsTo answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting.ResultsExpert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated.
  • Autores: Camacho, V. (Autor de correspondencia); Gomez-Grande, A.; Sopena, P.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN 2253-654X Vol.37 N° 6 2018 págs. 397 - 406
    Resumen
    Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased A beta(1-42) and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on F-18-FDG PET and temporal atrophy on MRI). Recently specific recommendations have been created as a consensus statement on the appropriate use of the imaging biomarkers, including amyloid PET: early-onset cognitive impairment/dementia, atypical forms of AD, mild cognitive impairment with early age of onset, and to differentiate between AD and other neurodegenerative diseases that occur with dementia. Amyloid PET is also contributing to the development of new therapies for AD, as well as in research studies for the study of other neurodegenerative diseases that occur with dementia where the deposition of A beta amyloid is involved in its pathogenesis. In this paper, we review some general concepts and study the use of amyloid PET in depth and its relationship with neurodegenerative diseases and other diagnostic techniques.
  • Autores: Nestor, P. J. (Autor de correspondencia); Altomare, D.; Festari, C. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1509 - 1525
    Resumen
    To assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer's disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia. A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method. The level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs-including those where study evidence was poor or lacking-based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed. Although there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.
  • Autores: Bouwman, F. (Autor de correspondencia); Orini, S.; Gandolfo, F.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° 9 2018 págs. 1526 - 1533
    Resumen
    A joint effort of the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) aims at clinical guidance for the use of FDG-PET in neurodegenerative diseases. This paper addresses the diagnostic utility of FDG-PET over clinical/neuropsychological assessment in the differentiation of the three forms of primary progressive aphasia (PPA). Seven panelists were appointed by the EANM and EAN and a literature search was performed by using harmonized PICO (Population, Intervention, Comparison, Outcome) question keywords. The studies were screened for eligibility, and data extracted to assess their methodological quality. Critical outcomes were accuracy indices in differentiating different PPA clinical forms. Subsequently Delphi rounds were held with the extracted data and quality assessment to reach a consensus based on both literature and expert opinion. Critical outcomes for this PICO were available in four of the examined papers. The level of formal evidence supporting clinical utility of FDG-PET in differentiating among PPA variants was considered as poor. However, the consensual recommendation was defined on Delphi round I, with six out of seven panelists supporting clinical use. Quantitative evidence demonstrating utility or lack thereof is still missing. Panelists decided consistently to provide interim support for clinical use based on the fact that a typical atrophy or metabolic pattern is needed for PPA according to the diagnostic criteria, and the synaptic failure detected by FDG-PET is an earlier phenomenon than atrophy. Also, a normal FDG-PET points to a non-neurodegenerative cause.
  • Autores: Nobili, F. (Autor de correspondencia); Arbizu Lostao, Javier; Bouwman, F.; et al.
    Revista: EUROPEAN JOURNAL OF NEUROLOGY
    ISSN 1351-5101 Vol.25 N° 10 2018 págs. 1201 - 1217
    Resumen
    Background and purposeRecommendations for using fluorodeoxyglucose positron emission tomography (FDG-PET) to support the diagnosis of dementing neurodegenerative disorders are sparse and poorly structured. MethodsTwenty-one questions on diagnostic issues and on semi-automated analysis to assist visual reading were defined. Literature was reviewed to assess study design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiver operating characteristic curve, and positive/negative likelihood ratio of FDG-PET in detecting the target conditions. Using the Delphi method, an expert panel voted for/against the use of FDG-PET based on published evidence and expert opinion. ResultsOf the 1435 papers, 58 papers provided proper quantitative assessment of test performance. The panel agreed on recommending FDG-PET for 14 questions: diagnosing mild cognitive impairment due to Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) or dementia with Lewy bodies (DLB); diagnosing atypical AD and pseudo-dementia; differentiating between AD and DLB, FTLD or vascular dementia, between DLB and FTLD, and between Parkinson's disease and progressive supranuclear palsy; suggesting underlying pathophysiology in corticobasal degeneration and progressive primary aphasia, and cortical dysfunction in Parkinson's disease; using semi-automated assessment to assist visual reading. Panellists did not support FDG-PET use for pre-clinical stages of neurodegenerative disorders, for amyotrophic lateral sclerosis and Huntington disease diagnoses, and for amyotrophic lateral sclerosis or Huntington-disease-related cognitive decline. ConclusionsDespite limited formal evidence, panellists deemed FDG-PET useful in the early and differential diagnosis of the main neurodegenerative disorders, and semi-automated assessment helpful to assist visual reading. These decisions are proposed as interim recommendations.
  • Autores: Guillen Valderrama, Edgar Fernando; Perez-Grijalba, V.; Prieto Azcárate, Elena; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° Supl. 1 2018 págs. S227 - S228
  • Autores: Casanovas, M. M. ; Percovich, J.; Bello, P. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° Supl. 1 2018 págs. S593 - S594
  • Autores: Casanovas, M. M. ; Percovich, J. ; Bello, P.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN 1619-7070 Vol.45 N° Supl. 1 2018 págs. S594

Proyectos desde 2018

  • Título: Correlación entre el depósito de tau, la disfunción neuronal y el fenotipo clínico en pacientes con Parálisis Progresiva Primaria: estudios de neuroimagen e Histología.
    Código de expediente: PI20/00245
    Investigador principal: JAVIER IGNACIO ARBIZU LOSTAO.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 95.590,00 €
    Fondos FEDER: SI
  • Título: Alteraciones de la sinapsis en el estriado y en la corteza frontal en la disfunción ejecutiva de la enfermedad de Parkinson
    Código de expediente: PI19/01915
    Investigador principal: MARIA CRUZ RODRIGUEZ OROZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 123.420,00 €
    Fondos FEDER: SI
  • Título: Descifrando la disociación de resultados en pruebas vestibulares de pacientes con enfermedad de Méniere unilateral
    Código de expediente: PI19/00414
    Investigador principal: NICOLAS PEREZ FERNANDEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 68.970,00 €
    Fondos FEDER: SI
  • Título: Neurodegeneración en epilepsia: ¿Una nueva Taupatía no descrita? Estudio in-vivo del depósito de proteina Tau en epilepsia temporal
    Código de expediente: PI19/00610
    Investigador principal: MARIA CENTENO SOLADANA, ASIER GOMEZ IBAÑEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 75.020,00 €
    Fondos FEDER: SI
  • Título: Optimización de la radiembolización hepática mediante un modelo de simulación computacional
    Código de expediente: PI18/00692
    Investigador principal: JOSE IGNACIO BILBAO JAUREGUIZAR, MARIA MACARENA RODRIGUEZ FRAILE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: AES2018 PI
    Fecha de inicio: 01-01-2019
    Fecha fin: 31-12-2022
    Importe concedido: 59.290,00 €
    Fondos FEDER: SI
  • Título: Desarrollo de técnicas de mapeado de la reactividad cerebrovascular. Aplicaciones en la cirugía de tumores cerebrales.
    Código de expediente: PI18/00084
    Investigador principal: MARIA ASUNCION FERNANDEZ SEARA.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: AES2018 PI
    Fecha de inicio: 01-01-2019
    Fecha fin: 31-12-2022
    Importe concedido: 62.920,00 €
    Fondos FEDER: SI
  • Título: Modulando el sistema inmune con adenovirus oncolíticos como estrategia para los tumores difusos de tronco (DIPGs).
    Código de expediente: PI16/00066
    Investigador principal: MARTA MARIA ALONSO ROLDAN.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2016 AES PROYECTOS DE INVESTIGACIÓN
    Fecha de inicio: 01-01-2017
    Fecha fin: 31-12-2019
    Importe concedido: 86.515,00 €
    Fondos FEDER: SI
  • Título: Enfermedades Vasculares Cerebrales (INVICTUS)
    Código de expediente: RD16/0019/0016
    Investigador principal: EDUARDO ANTONIO MARTINEZ VILA.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2016 AES REDES
    Fecha de inicio: 01-01-2017
    Fecha fin: 31-12-2021
    Importe concedido: 23.897,50 €
    Fondos FEDER: SI
  • Título: Evaluación del impacto de la imagen pet de Amiloide - beta en el diagnóstico y control clínico de los pacientes con deterioro cognitivo evaluados por sospecha de enfermedad de Alzheimer (EA)
    Código de expediente: DTS15/00141
    Investigador principal: JAVIER IGNACIO ARBIZU LOSTAO.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2015 AES DESARROLLO TECNOLÓGICO EN SALUD
    Fecha de inicio: 01-01-2016
    Fecha fin: 31-12-2018
    Importe concedido: 59.139,00 €
    Fondos FEDER: NO